Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

20 Jun 2014 13:56

Sector movers: Shire soars as M&A fever boosts pharma, health stocks

News that Shire has rejected a £27bn approach by AbbVie sent shares in the pharmaceutical and healthcare equipment sectors higher on Friday as yet more M&A continued to give sentiment a boost. "A bit of M&A excitement has been just the ticket to enliven trading on what may otherwise have been somet

Read more
17 Jun 2014 09:19

UK BROKER RATINGS: Davy Upgrades Easyjet To Outperform

LONDON (Alliance News) - The following UK shares received analyst recommendations Tuesday morning:
----------
FTSE 100
----------
BERENBERG INITIATES BAE SYSTEMS WITH 'HOLD' - TARGET 445 PENCE
----------
BERENBERG INITIATES GKN WITH 'BUY' - TARGE

Read more
30 May 2014 16:15

Hasard Global founder acquires shares worth £1.8m

The Non-Executive Chairman and founder of Hansard Global, Dr Leonard Polonsky, has increased his stake in the specialist long-term savings provider with the purchase of two million shares. Taking his stake in the group to 41.34%, Polonsky spent 90p a share at a total trade value of £1.8m. The de

Read more
30 May 2014 11:08

DIRECTOR DEALINGS: Vectura Chief Executive Exercises Options, Sells Shares

LONDON (Alliance News) - Vectura Group PLC Friday said Chief Executive Chris Blackwell exercised options over 1.7 million shares and subsequently sold 1.1 million shares to meet tax liabilities at a price 131 pence per share. Following this transaction Blackwell now holds 1.3 million shares

Read more
30 May 2014 09:14

Friday broker round-up UPDATE

ASOS: N+1 Singer reduces target price from 5300p to 4100p, while staying with its hold recommendation. Cairn Energy: JP Morgan cuts target price from 315p to 279p and maintains an overweight rating. Cobham: Canaccord Genuity increases target price from 285p to 320p and reiterates a hold recommenda

Read more
30 May 2014 09:13

UK BROKER RATINGS: Citigroup, Numis Raise Mitchells & Butlers To Buy

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
UBS RAISES SMITH & NEPHEW PRICE TARGET TO 1100 (1000) PENCE - 'BUY'
----------
UBS REMOVES RANDGOLD RESOURCES FRO

Read more
21 May 2014 12:19

Vectura revenues ahead of forecasts

Pulmonary drug delivery company Vectura released encouraging results after a transformational year, with revenues ahead of expectations thanks to growing royalty income. The Wiltshire company reached positive earnings before interest, tax, depreciation and amortisation (EBITDA) of £5.2m in the year

Read more
21 May 2014 10:52

Vectura Narrows Annual Loss On 20% Revenue Increase

LONDON (Alliance News) - Respiratory treatment development company Vectura Group PLC Wednesday said it more than halved its losses in its recent financial year, after reporting a 20% increase in revenues, due to a substantial increase in royalty revenues. For the year ended March 31, the gr

Read more
21 May 2014 09:18

UPDATE 2-Vectura revenue jumps on royalty push, sees more growth

* FY revenue jumps 20 pct to 36.5 mln stg * Royalty revenue rises 25 pct to 16.3 mln stg * Shares rise as much as 3.5 pct (Adds CEO and analyst comments; updates share movement) May 21 (Reuters) - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenu

Read more
21 May 2014 08:36

Wednesday broker round-up UPDATE

African Minerals: Citi reduces target price from 260p to 190p, while leaving its buy recommendation unchanged. Alliance Pharma: Numis lowers target price from 39p to 37p and maintains an add rating. APR Energy: JP Morgan shifts target price from 1082p to 1089p keeping its overweight rating. Astra

Read more
21 May 2014 06:31

Vectura revenue rises 20 pct on higher royalty payments

May 21 (Reuters) - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenue as it benefited from higher royalty payments for drugs it has licensed. The company, which develops and markets drugs for asthma and chronic obstructive pulmonary disease, said pretax loss n

Read more
21 May 2014 05:10

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
20 May 2014 15:27

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
20 May 2014 05:36

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more
19 May 2014 15:41

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar 
Read more

Quickpicks are a member only feature

Login to your account